Abstract:Objective HIV-1 management has advanced significantly with antiretroviral therapy (ART), yet challenges persist, including low-level HIV-1 viraemia (LLV). LLV presents a complex scenario, with varied definitions in the literature, reflecting uncertainties in its clinical interpretation. Questions arise regarding the underlying mechanisms of LLV, whether it signifies ongoing viral replication or stems from other factors. This study aimed to systematically review strategies for LLV management, providing insights into optimal clinical approaches. Methods MEDLINE, EMBASE, Cochrane Library, Web of Science and Canadian Agency for Drugs and Technologies in Health were searched for relevant literature on LLV management. We included studies published between 2004 and 2024, assessing interventions such as ART modification, genotypic resistance testing, adherence assessment, performing therapeutic drug monitoring, testing for chronic coinfections and assessing the viral reservoir via HIV DNA quantification. Meta-analyses were conducted where feasible. Results The systematic review identified 48 eligible records. Findings indicated limited evidence supporting the effectiveness of ART regimen modification in achieving virological suppression among individuals with LLV. However, studies assessing genotypic resistance testing revealed a significant association between resistance-associated mutations and virological suppression during LLV. Adherence to ART emerged as a critical determinant of treatment efficacy, with interventions showing promise in achieving viral suppression. The clinical utility of therapeutic drug monitoring in managing LLV remained inconclusive. Gaps in the literature were identified regarding follow-up scheduling, managing concurrent chronic infections and assessing inflammatory markers in LLV management. Conclusions While ART modification may not consistently achieve virological suppression, genotypic resistance testing may offer insights into treatment outcomes. Adherence to ART emerged as a crucial factor, necessitating tailored interventions. However, further research is needed to elucidate the clinical utility of therapeutic drug monitoring and other management strategies. The study highlights the importance of ongoing research to refine therapeutic approaches and improve patient outcomes in LLV management. PROSPERO registration number CRD42024511492.

Consequences of low-level viremia among women with HIV in the United States

Low level viremia is associated with Serious Non-AIDS Events in People Living with HIV

Clinical Significance and Management of Low-Level HIV Viremia in the Era of Integrase Strand Transfer Inhibitors

Low-level HIV-1 viremia affects T-cell activation and senescence in long-term treated adults in the INSTI era

Influencing factors and clinical significance of hypoviremia in HIV

Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy

The Impact of Low-Level Viraemia on Virological Failure—Results From a Multicenter HIV Antiretroviral Therapy Cohort Study in Yunnan, China

Clinical Relevance of Human Immunodeficiency Virus Low-level Viremia in the Dolutegravir era: Data From the Viral Load Cohort North-East Lesotho (VICONEL)

Impact of low-level viremia with drug resistance on CD4 cell counts among people living with HIV on antiretroviral treatment in China

Risk Factors and Clinical Prediction Models for Low-Level Viremia in People Living with HIV Receiving Antiretroviral Therapy: an 11-Year Retrospective Study

Analysis of virologic outcome in low-level HIV-1 viremia patients in a small cohort

Managing low-level HIV viraemia in antiretroviral therapy: a systematic review and meta-analysis

HIV‐1 low‐level viraemia predicts virological failure in first‐line and second‐line ART‐experienced individuals in India: A retrospective longitudinal study

Successful Virologic Outcomes over Time among HAART-treated HIV-infected Patients.

Management of low-level HIV viremia during antiretroviral therapy: Delphi consensus statement and appraisal of the evidence

Dynamics of Low-Level Viremia and Immune Activation after Switching to a Darunavir-Based Regimen

Low level HIV viremia is more frequent under protease-inhibitor containing firstline therapy than under NNRTI-regimens

Low-level viraemia and virologic failure among people living with HIV who received maintenance therapy with co-formulated bictegravir, emtricitabine and tenofovir alafenamide versus dolutegravir-based regimens

Low-Level Viremia among Adults Living with HIV on Dolutegravir-Based First-Line Antiretroviral Therapy Is a Predictor of Virological Failure in Botswana

Incidence of low-level viremia and its impact on virologic failure among people living with HIV-1 who switched to elvitegravir-based antiretroviral therapy

Predictors of Detectable Viremia, Outcomes, and Implications for Management of People Living With HIV Who Are Receiving Antiretroviral Therapy in Southern Nigeria